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Abstract
The European Society of Breast Radiology (EUSOBI) established an International Breast DWI working group. The working group
consists of clinical breast MRI experts, MRI physicists, and representatives from large vendors of MRI equipment, invited based upon
proven expertise in breastMRI and/or in particular breast DWI, representing 25 sites from 16 countries. The aims of the working group
are (a) to promote the use of breast DWI into clinical practice by issuing consensus statements and initiate collaborative research where
appropriate; (b) to define necessary standards and provide practical guidance for clinical application of breast DWI; (c) to develop a
standardized and translatable multisite multivendor quality assurance protocol, especially for multisite research studies; (d) to find
consensus on optimal methods for image processing/analysis, visualization, and interpretation; and (e) to work collaboratively with
system vendors to improve breast DWI sequences. First consensus recommendations, presented in this paper, include acquisition
parameters for standard breast DWI sequences including specifications of b values, fat saturation, spatial resolution, and repetition and
echo times. To describe lesions in an objectiveway, levels of diffusion restriction/hindrance in the breast have been defined based on the
published literature on breast DWI. The use of a small ROI placed on the darkest part of the lesion on the ADCmap, avoiding necrotic,
noisy or non-enhancing lesion voxels is currently recommended. The working group emphasizes the need for standardization and
quality assurance before ADC thresholds are applied. Theworking group encourages further research in advanced diffusion techniques
and tailored DWI strategies for specific indications.
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Key Points
• The working group considers breast DWI an essential part of a multiparametric breast MRI protocol and encourages its use.
• Basic requirements for routine clinical application of breast DWI are provided, including recommendations on b values, fat
saturation, spatial resolution, and other sequence parameters.
• Diffusion levels in breast lesions are defined based on meta-analysis data and methods to obtain a reliable ADC value are detailed.
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Abbreviations
EUSOBI European Society of Breast Imaging
QIB Quantitative imaging biomarker
SNR Signal-to-noise ratio
SPAIR Spectrally adiabatic inversion recovery
STIR Short tau inversion recovery
Introduction
Diffusion-weighted imaging (DWI) is emerging as a key im-
aging technique to complement dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) of the breast. DWI
can be used to distinguish between benign and malignant
breast lesions [1–13], stratify in situ from invasive disease
[14–18], and potentially predict the response to and monitor
the effect of neoadjuvant treatment over time [19–25].
Excellent reviews can be found in the literature; however,
there is still no clear consensus within the literature on where
and how breast DWI should be applied.
A major strength of DWI is that the apparent diffusion
coefficient (ADC) can be derived from it, providing a
quantitative measure of observed diffusion restriction. We
use the term “restriction” because it is widely used in the
breast DWI literature. However, the term refers specifically
to water diffusion in enclosed spaces, whereas ADC is
sensitive to multiple processes occurring in human tissue
(genuine restricted intracellular motion, compartmental ex-
change due to cell membrane permeability, hindered extra-
cellular motion, water bounding to macromolecules, blood
microcirculation, etc.) [26]. Thus, the term “hindrance” is
also used in literature to describe diffusion effects and
might be a more accurate description. Advanced protocols
and analyses (as discussed later in this statement) may be
used to (partly) disambiguate these effects. However, the
focus of this statement is on increasing the translation and
standardization of DWI for breast cancer evaluation using
the established ADC quantification.
A current challenge is the large variability in results,
i.e., specificity, sensitivity and thresholds, reported for
ADC in distinguishing between benign and malignant
breast lesions [9]. A less evident challenge is the inconsis-
tent image quality due to different MRI system capabilities
as well as equipment and imaging sequences/protocols
contributing to a perceived limited usefulness of DWI in
clinical practice. These challenges, coupled with the lack
of prospectively validated thresholds for supporting diag-
nostic decisions, have prevented DWI from becoming an
established measure that can be easily incorporated into the
Breast Imaging Reporting and Data System (BI-RADS,
[27]). Nevertheless, DWI has been incorporated (albeit in
a qualitative way) into the Prostate Imaging Reporting and
Data System (PI-RADS) [28].
In spite of the diversity in DWI protocols (e.g., the lack of
standardization and the presence of artifacts), ADC estimation
and interpretation methods across clinical sites [9, 29], and
composition of breast lesions in the studies [21, 30–33], there
is common agreement that DWI is sensitive to tissue micro-
structure and cellularity and provides quantitative information
that can be used for lesion characterization. The improved
lesion characterization can reduce the number of unnecessary
biopsy recommendations [6, 7, 34, 35], which has been further
validated in a multicenter trial [13]. The quantitative nature of
ADC measures combined with relatively short acquisition
times, typically in the order of 2–4 min but not exceeding 5
min, makes it an ideal imaging biomarker candidate [36].
Consequently, there is great interest to improve the generaliz-
ability and reproducibility of breast DWI across institutions
and imaging platforms. Moreover, although technically chal-
lenging, DWI protocol standardization between different sys-
tems and vendors has been achieved in the breast and other
organs [21, 24, 37–39].
The International Breast DWI Working Group
To address the above-described issues and support standard-
ized implementation of DWI, promote its clinical use, and
facilitate its adoption as an integral part of breast MRI inter-
pretation within BI-RADS, an International Breast DWI
Working Group was established by the European Society of
Breast Radiology (EUSOBI). Members of the working group
were invited based upon proven expertise in breast MRI and/
or breast DWI, representing 25 sites from 16 countries.Within
the working group, a scientific committee was appointed. The
full composition of the working group is given in Appendix 1.
The primary goals of the International Breast DWIworking
group are:
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& To promote the integration of DWI into clinical practice
by issuing consensus statements and initiate collaborative
research where appropriate
& To define standards and provide practical guidance for
clinical application of DWI
& To develop a standardized and translatable multisite
multivendor quality assurance protocol, especially for
multisite research studies
& To find consensus on optimal methods for image process-
ing/analysis, visualization, and interpretation
& To work collaboratively with system vendors to improve
breast DWI sequences
Members of the working group were first invited to provide
information on their protocols with details of acquisition and
processing parameters. This revealed substantial heterogene-
ity of applied DWI protocols, even among experts. The mem-
bers of the Scientific Committee were then surveyedwith a list
of points on basic requirements, acquisition parameters, hard-
ware, quality control, analysis and reporting to define the min-
imum standards for breast DWI, along with technical recom-
mendations to meet these standards.
In this statement, we report the requirements for breast DWI
that obtained general consensual agreement. The items that
reached more than 80% consensus are shown in the
Supplementary Material. This general guidance should be used
to provide consistency across clinical trials and in clinical practice.
The group acknowledges that there are many items that may
influence both the acquisition and reporting of breast DWI that
are not discussed in detail in this statement. Those items did not
reach consensus at this stage, requiring further discussion and/or
more extensive research. Some of these issues include field
strength effects, diffusion gradient waveform dependence, image
registration, eddy current distortion and compensation, and gra-
dient nonlinearity correction. Each of these topics has received
attention in the breast DWI literature (see below), providing a
roadmap for their incorporation in a consensus process. In that
spirit, further work is intended from subgroups of our working
group to methodically address such items, especially regarding
clinical implementation, standardization and quality control, and
advanced diffusionMRI methods. The results of these efforts are
to be presented in a second round of topical guidelines.
When to perform breast DWI?
Breast DWI may be part of any multiparametric breast MRI
protocol independent of the clinical indication for MRI, as DWI
improves the characterization of lesions detected by contrast-
enhanced MRI irrespective of the indication [6, 7, 34, 35, 40].
This includes breast MRI performed for pre-operative staging of
known breast cancer (ipsi- and contralateral), monitoring neoad-
juvant systemic therapy, evaluating carcinomas of unknown
primary origin, resolving equivocal findings from other imaging
modalities, and solving problem. For all these indications, breast
DWI is considered an important addition to DCE-MRI to im-
prove specificity, with the aim of reducing the number of recalls
and biopsies of benign breast lesions. Amore detailed description
of current indications for breast MRI is found in existing guide-
lines from the EUSOBI, European Society of Breast Cancer
Specialists, and American College of Radiology [41–43].
The working group highlights a special case: the applica-
tion of breast DWI for breast cancer screening. There is not yet
enough evidence to recommend for or against the inclusion of
DWI in screening protocols. While DWI may improve lesion
classification in this setting, its use should be balanced against
the limited frequency of abnormal findings (because in screen-
ing, most exams are normal). For example, rather than
performing DWI in all screening examinations, in order to
prevent unnecessary biopsies, a multiparametric MRI includ-
ing DWI could be performed as a secondary evaluation in
women with ambiguous findings at the screening test.
Could breast DWI be used as a stand-alone test
for breast cancer detection?
In general, even though breast DWI has high specificity for
lesion characterization, the sensitivity of DCE-MRI still ex-
ceeds that of breast DWI [41–45], albeit the sensitivity of
DWI alone may be equal to or even higher than that of com-
monly used screening techniques such as mammography and
ultrasound. Thus, currently, its use for cancer detection as part
of an unenhanced MRI examination requires further investi-
gation and should be considered only in cases where DCE-
MRI is not accessible or not appropriate. In particular, DWI
may be a valuable alternative option in patients with contra-
indications to gadolinium-based contrast agents (such as pa-
tients with severe kidney dysfunction at risk of nephrogenic
systemic fibrosis and patients with a previous acute reaction to
a gadolinium-based contrast agent [44]).
Is breast DWI helpful in the assessment of implants?
Breast DWI is not helpful in the assessment of breast implant
integrity, which relies on other dedicated non-contrast tech-
niques such as T2-weighted imaging and silicone specific se-
quences and thus is not needed for this purpose. It is, however,
as useful as in any other indication for lesion classification in
patients with implants.
What are the minimal technical requirements
for breast DWI?
The working group found consensus on a minimal set of ac-
quisition parameters to be met in clinical practice. Adherence
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to these minimal requirements should improve the comparison
of ADC values from site to site, which is an important step
towards the generalizability required to eventually incorporate
ADC quantification into standardized guidelines (e.g., BI-
RADS).
Which hardware should be used for breast DWI?
Breast DWI should be undertaken in a closed bore magnet
with field a strength of 1.5 T or more. The gradient hard-
ware should be capable of reaching a maximum gradient
strength of at least 30 mT/m, and the use of a dedicated
breast coil with at least four channels is strongly recom-
mended. When possible, DWI should be performed before
DCE-MRI, as the presence of contrast agents may physi-
cally reduce measured ADC values. It should be men-
tioned, however, that no significant effect has been shown
on overall diagnostic performance when DWI is obtained
after contrast administration as long as fat suppression
using the STIR technique is avoided [5, 9, 45].
What sequence type and parameters are
recommended for breast DWI?
The recommended minimal requirements for breast DWI are
shown in Table 1. The working group acknowledges that for
different MRI systems, different parameters might need to be
adapted in order to obtain the best possible results. Therefore,
Table 1 should be regarded as a guide rather than as a checklist
for optimizing a DWI sequence. For instance, the axial orien-
tation was motivated by anatomy and ease of interpretation
more than technical optimization, which depends on the coil
configuration. Specifying more parameters is beyond the
scope of this paper but will be addressed at a later stage.
Single-shot or multi-shot echo-planar imaging (EPI) is
regarded as baseline techniques for DWI acquisition. EPI
Table 1 Minimum requirements
for diffusion-weighted-imaging
of the breast as per working group
consensus
Acquisition parameter Minimum requirement Specific remarks
Type of sequence EPI based
Orientation Axial
Field of view The field of view should
cover both breasts
Covering the axillary region is not
mandatory
In-plane resolution ≤ 2 × 2 mm2 Acquired physical resolution, before
reconstruction, and reconstructed
resolution
Slice thickness ≤ 4 mm
Number of b values 2 More is optional
Lowest b value 0 s/mm2 In practice as close to 0 as possible,
but not exceeding 50 s/mm2
High b value 800 s/mm2
Fat saturation Required SPAIR is recommended
TE Minimum possible by the
system and choice of
parameters
Optimize the rBW to obtain minimum
TE. The reduction in SNR by
increasing the rBW is usually
compensated for by the shortening
of TE
TR ≥ 3000 ms
Acceleration Parallel imaging (factor ≥ 2) Reduces distortion, loss in SNR can
be counterbalanced by increasing
the number of excitations
Post-processing Generation of ADC
maps is required
Standard ADC is calculated as ADC = ln
(Slow/Shigh) / (bhigh−blow) where Slow,high
are the image signal values obtained with
b values blow,high
It should be understood that the suggested in-plane resolution also corresponds to the physical resolution of the
native images. Acquisition parameters aimed at reducing acquisition times or improving image quality (e.g., phase
resolution) may introduce significant differences between the prescribed image resolution and the actual acquired
resolution. Reconstruction and post-processing (e.g., interpolation) may also alter the native image resolution.
Support from vendor technicians may be helpful when in doubt
EPI, echo-planar imaging; rBW, receiver bandwith; SPAIR, spectrally adiabatic inversion recovery; TE, echo time;
TR, repetition time
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has a wide breadth of applications and a correspondingly deep
library of tools to address its shortcomings in image quality.
Examples are nonlinearities in diffusion gradients, eddy cur-
rent or magnetic field–induced image distortions, and motion.
Gradient nonlinearities have been identified as a major source
of inaccuracy for breast DWI [46], and prescriptions for cor-
rection have been offered [47]. Eddy current and inhomoge-
neous field distortions are well-known issues for diffusion
MRI with evolving solutions. Inhomogeneous field distortion
correction [48] and motion correction strategies [49] have
been applied to breast DWI. Multi-shot EPI, especially within
the RESOLVE sequence framework [50] has the potential to
reduce susceptibility-induced geometric distortion and motion
artifacts, at the expense of the acquisition time. However,
corrective elements for breast DWI acquisitions are currently
not sufficiently standardized to recommend a specific ap-
proach and will be addressed in future work of our working
group. Nonetheless, the group made a recommendation on
using an acceleration factor of 2, which reduces eddy current
effects (and distortion). Vendor-based standard product pulse
sequences with inline workflow elements (eddy current cor-
rection, gradient nonlinearity correction) may be used, but the
optimal correction strategies are yet unknown.
Which b values should be chosen for breast DWI?
The choice of b values is critical. Due to the non-Gaussian
nature of water diffusion in tissues (which results in a curva-
ture of the DWI signal attenuation plot across b values), the
ADC value is highly dependent on the choice of b values, with
the ADC values getting smaller as larger b values are used
(Fig. 1). Higher b values may increase the specificity of DWI
[11] and also lead to a decreased signal-to-noise ratio. A high
b value of 800 s/mm2 was chosen by the group as a good
compromise for standardization. This value can be established
theoretically [51] and is backed up by empirical evidence [9].
Fig. 1 Diffusion MRI signal decay versus b value. a The diffusion signal
attenuation (logarithmic signal attenuation versus b value) follows a
straight line when diffusion is free (dotted green line). In tissues,
hindrance/restriction of water diffusion by many microscopic obstacles
results in a reduced rate of raw signal attenuation and a curvature (cross
symbols) which increases with the b value. The ADC value (for instance,
calculated from b = 0 and 800 s/mm2) is, thus, lower than the free diffu-
sion coefficient, due to these combined effects. At high b values, the
signal may further reach a “noise floor” and no more diffusion informa-
tion can be extracted. Conversely, at very low b values, the signal
attenuation rate can be elevated, because blood circulation in the random
capillary network mimics diffusion (pseudo-diffusion, which is referred
to as intravoxel incoherent motion (IVIM)). b The conceptual diagram
illustrates the need for standardization of the applied b values. As the
ADC value is calculated assuming a linear signal decay while the actual
signal attenuation is curved, the ADC value decreases when using higher
b values, as more restriction/hindrance effects are integrated into the ADC
value; this illustrates the importance of using common b values for
standardization
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In how many directions should breast DWI be
acquired?
The number of directions to acquire diffusion measurements
from which the final ADC is calculated can vary from one
direction to more than 6 directions for diffusion tensor imag-
ing (DTI). Using several different diffusion directions allows
calculation of an average ADC and reduces the influence of
anisotropy in the tissue, thus improving generalizability. The
“3 orthogonal directions” method (commonly available clini-
cally and less time consuming than the 6 directions scheme
required for DTI) provides an approximate isotropic
weighting (a.k.a. pseudo trace-weighting contrast as an ap-
proximation to the true trace which can be obtained from the
eigenvalue average derived from the full diffusion tensor).
This 3 directions approach may also mitigate residual varia-
tions of b values across directions. However, variable eddy
current interactions with the EPI readout train may result in
different image distortions according to the diffusion-
encoding direction, which, when averaged over the 3 direc-
tions, can confound image quality and reduce sensitivity to
small lesions. Alternatively, acquisitions along only 1 direc-
tion but using gradient pulses simultaneously on 2 or 3 axes
(sometimes called “diagonal”) allow high b values to be
reached using shorter TEs, thus increasing SNR and reducing
acquisition time compared with a sequential 3 direction acqui-
sition. Diagonal diffusion gradients, however, would intro-
duce variability in the presence of diffusion anisotropy known
to exist in fibroglandular breast tissue. Given these mixed
advantages, the compromise recommended is to utilize 3 or-
thogonal directions. This scheme is universally available and
provides approximately isotropic contrast. However, we must
emphasize that this approach can introduce non-negligible
error and bias in the estimation of diffusion kurtosis
imaging-derived indices of the breast and is thus not appro-
priate for this application [52].
How can high image quality and SNR be ensured?
The signal-to-noise ratio (SNR) of DWI is also important,
especially when a high b value is used as ADC values may
be largely underestimated (mimicking malignant tissues)
Fig. 2 An example of the effect of the noise floor on the observed ADC
values. For three hypothetical tissues with free diffusion (no hindrance/
restriction effect for simplicity), in the absence of noise (left), the slope
gives the ADC values of 1.0, 1.5, and 2.0 10-3 mm2/s, respectively, for
tissues A, B, and C. However, in the presence of noise (right), the noise
floor leads to curvature of the signal decay. As a result, the ADC values
change. In this example, we measured 0.6, 1.22, and 1.08 10-3 mm2/s,
respectively, for tissues A, B, and C. It should be noted that the observed
ADC value in tissue B is now higher than that in tissue C. This order no
longer reflects diffusion, but the amount of signal at b = 0 s/mm2, which
depends solely on tissuemagnetization properties (A has the lowest signal
level and B the highest). Consequently, a low SNRmay result in misclas-
sification of the diffusion level of a lesion. S0 indicates the signal intensity
at b = 0 s/mm2, and D = diffusion coefficient
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when the SNR is low (Fig. 2). This requires that a sufficiently
high SNR is achieved. One qualitative requirement in that
vein is that fibroglandular tissue (FGT) (if present) should
be well depicted on low b value images. Quantitatively, while
the term “sufficient SNR” has yet to be defined in DWI of the
breast, acquisition with multiple excitations for averaging, es-
pecially at b = 800 s/mm2, will be necessary to reach this goal.
Unfortunately, the working group acknowledges that there are
currently no universal methods to quantify SNR easily in a
clinical setting, especially with the use of multichannel coils.
In that setting, prescriptions exist for accurate SNR determi-
nation using difference methods [53] for average noise assess-
ment or the Kellman approach [54] for spatially varying SNR,
but they require additional acquisitions and advanced recon-
struction that are not sufficiently ubiquitous to reach a consen-
sus recommendation. Consequently, before implementing a
new DWI sequence in routine clinical care, it is advisable to
first test the sequence and assess image quality qualitatively.
Ideally, quality control should be performed using dedicated
calibrated phantoms with known ADC values, especially for
multicenter studies (see below). Such phantoms will also al-
low the correct application of diffusion gradients (i.e., b values
across axes) to be checked. In clinical practice, it remains
important to check regularly whether the obtained diffusion
images have a sufficient SNR and are reasonably free of struc-
tural artefacts that might hamper interpretation. While previ-
ous studies have addressed quality controls in DWI in general
[55–57], one study investigated in detail factors influencing
SNR and quantitative ADCmeasures in breast DWI [58]. The
results of this study corroborate the hypothesis that scanners
should be adequately characterized in breast DWI. Quality
control is also required after the maintenance of the MRI sys-
tem and after each upgrade of hard- and/or software.
Apart from low SNR, a commonly encountered problem is
insufficient fat suppression, which leads to ghosting and po-
tentially to underestimation of ADC values. Spectral attenuat-
ed inversion recovery (SPAIR), which employs both T1 con-
trast and spectral selectivity, is recommended given a moder-
ate preference in literature in comparison with short tau inver-
sion recovery (STIR) [59, 60] and based on the consensus
among the panel. However, if unsuccessful, STIR may be an
acceptable alternative as this technique is independent fromB0
field inhomogeneity [61].
While not listed in Table 1, diffusion time is a parameter
that may significantly impact ADC values. Although it is gen-
erally hidden to users (gradient pulse time course is usually
not reported), with conventional sequences, diffusion time is
approximately equal to TE/2. The degree of diffusion restric-
tion (or hindrance) decreases at short diffusion times (increas-
ing the ADC) [62] and it is important to be aware of this
parameter as some vendors are now proposing stronger gradi-
ent hardware that allows shorter diffusion times. However, on
most clinical MRI scanners, achievable diffusion times cannot
be shortened below ~ 25 ms, which leads to comparable re-
sults between machines.
How to evaluate and interpret breast DWI?
How are lesions identified on breast DWI?
In a multiparametric breast MRI protocol, lesion detection
should be primarily based on evaluation of the contrast-
enhanced sequences, which can be aided by inspection of
the b = 800 s/mm2 images. On the b = 800 s/mm2 images,
cancers are typically hyperintense given adequate baseline T2
signal. As the basic DWI sequence is T2-weighted, lesions
with higher water content (e.g., cysts, myxoid fibroadenoma,
highly proliferative cancer) will show a high signal on low b
value images and may retain a (relatively) high signal on high
b value images. Consequently, a high signal on b = 800 s/mm2
images may be due to a very high T2 signal (commonly
referred to as T2 shine-through, although physically
misleading) or true diffusion restriction with little signal de-
crease of a moderately high T2 signal. Cross-correlation of b =
800 s/mm2 image findings with quantitative ADC maps usu-
ally allows discrimination between these instances. Therefore,
DWI analysis requires the evaluation of raw DWI data and
ADC maps together.
On the other hand, tissues and lesions with a very low water
content (e.g., fibrotic parenchyma, scars, some invasive lobular
cancers) may demonstrate a very low signal at b = 0 s/mm2 (and
thus, also on b = 800 s/mm2). Thus, these lesions will be diffi-
cult to visualize. In these lesions, the measurement of diffusion-
dependent signal loss may not be possible, thus preventing an
accurate assessment of diffusion level (Fig. 3). ADC in this
condition (that can be referred to as signal blackout) will be
low but will not reflect a true diffusion restriction (Fig. 3).
Can lesion location, size, andmorphology be assessed
on DWI images?
Assessment of location, size, and morphology of lesions is
possible on DW images, even though this is limited by a
spatial resolution that is inferior to that found in anatomical
and contrast-enhanced sequences, and when available, these
should be interpreted together. Morphologic assessment on
breast DWI may be reported when it is discrepant with other
sequences. Lesions can be categorized as foci, masses, or non-
mass lesions. For masses, shape (round, oval, irregular) and
internal signal pattern (homogeneous, heterogeneous, rim)
can be reported while in non-mass lesions, distribution (focal,
regional, linear, segmental) and internal signal pattern (homo-
geneous, heterogeneous) can be reported.
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How should the ADC value be measured after DWI
acquisition?
The pixel-wise parametric ADC maps enable quantitative as-
sessment of diffusion restriction or hindrance, which should
always be measured. The ADC value is obtained by drawing a
region of interest (ROI) on the lesion on the ADC map (or the
b = 800 s/mm2 image when the workstation allows propaga-
tion of the ROI to the ADC map). The ROI should fall
completely within the lesion, contain at least 3 voxels and
avoid both artifacts and necrotic or hemorrhagic parts of the
lesion. This implies that lesions of 6 mm or larger in the axial
plane are evaluable with DWI, albeit for small lesions, partial
volume effects should be taken into account. While there was
no consensus from our group on the size of the ROI to be used
(whole lesion or focused ROI), literature suggests that
selecting the lowest ADC value within the lesion (potentially
reflecting the most active part of the lesion) might provide a
more accurate discrimination between malignant and benign
breast lesions [17, 29, 63, 64]. Due to the above described
signal blackout, the ROI should fall within the enhancing part
of the lesion (and hyperintense part on DW images) in order to
avoid falsely low ADC values. Using a small ROI in the
darkest part of the lesion on ADC maps is analogous to that
used for analysis of DCE images. We thus suggest the use of a
ROI placed on the darkest part of the ADC map, avoiding
necrotic, noisy, or non-enhancing lesion voxels as the pre-
ferred method for measuring ADC values in order to reduce
inter- and intra-reader variability and improve breast DWI
consistency and comparability between sites. For such an
ROI, the mean ADC value within the ROI should be reported,
and it is suggested that the units should be in 10-3 mm2/s.
Volumetric sampling of the whole lesion may be useful when
the clinical indication is the evaluation of tumor response. In
any case, the type of ROI (whole or focused) used for lesion
assessment should be reported.
How is the ADC value interpreted?
Based on ADC measurements and lesion appearance, the pro-
posed classification of diffusion level in lesions is very low,
low, intermediate, high, and very high (Table 2 and Fig. 4).
Figure 4 shows corresponding ADC ranges based on the most
recent meta-analysis of studies evaluating DWI for the differ-
entiation of benign andmalignant lesions [10] and considering
only those studies that were in line with our consensus b value
suggestions. The ADC values provided in Table 2 are solely
intended to describe lesions in an objective way according to
their diffusion level. Lesion classification should not be based
upon diffusion level alone but should always be performed in
conjunction with all anatomical and functional information
available from all other imaging data.
Of the malignant lesions, invasive ductal and invasive lob-
ular cancers, as well as DCIS with microinvasion, are usually
associated with low to very low diffusion levels [16, 18, 65,
66]; pure ductal carcinoma in situ generally shows low or
intermediate diffusion (16), whereas particularly invasive mu-
cinous cancer may present with intermediate or even high
diffusion levels [67]; and triple-negative cancers with exten-
sive necrosis may also yield high or very high diffusion levels
in the necrotic part [68]. Typical examples of benign and ma-
lignant lesions are presented in Fig. 5.
ADC measurements are prone to bias from adjacent noise
regions (e.g., from voxels containing fat). These can be iden-
tified by unrealistically high (> 3 × 10-3 mm2/s), low (< 0.5 ×
Fig. 3 Observed signal decay in benign and malignant lesions depending
on baseline T2 signal. Tissues and lesions with a very low water content
(e.g., fibrotic parenchyma, scars, low cellular cancers with extensive
desmoplastic stromal fibrosis) may not be visible on high b value
images and present with an artefactual low signal decay leading to low
ADC values. S0 indicates signal intensity at b = 0 s/mm2
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10-3 mm2/s) or even zero/negative ADC values. Unrealistic
ADC values may require repositioning of the ROI.
Why are specific quantitative cut-off values not
provided?
Two goals of the working group are (a) to promote more
widespread integration of DWI into clinical use with standard-
ized acquisitions, increasing the global evidence base by in-
clusion of DWI in future clinical trials and (b) to derive quan-
titative discrimination levels supported by standardized and
reproducible acquisitions to be incorporated into clinical diag-
nostic or prognostic guidelines. A practical reality is that these
goals are symbiotic and achieving them is an unavoidably
iterative process. Thus, the analysis and interpretation scheme
based on both qualitative and preliminary quantitative features
(ADC value ranges) presented here are preliminary. It is im-
portant to realize that these suggestions are not fully vet-
ted by the procedures of quality control, reproducibility,
and multisite concordance that underpin formalized quan-
titative imaging biomarkers (QIB) and thus may evolve
with time. This process will also be amplified by the in-
corporation of experimental optimization (eddy current
distortion correction, gradient nonlinearity correction) into
the consensus process.
Consequently, the ADC values in Table 2 may be ad-
justed by our group in the future once more rigorous
standardization guidelines are in place, based upon
intended multicenter investigation. Similarly, the minimal
consensus recommendations of this document may be
Table 2 Suggested diffusion
level lexicon based on lesion
appearance on b = 800 s/mm2
images, ADC maps, and ADC
values
Diffusion level Lesion appearance on b800 and ADC maps a ADC value rangeb, c
Very low b800, very hyperintense
ADC, very hypointense
≤ 0.9 × 10-3 mm2/s
Low b800, hyperintense
ADC, hypointense
0.9–1.3 × 10-3 mm2/s
Intermediate b800, moderately hyperintense
ADC, moderately hypointense
1.3–1.7 × 10-3 mm2/s
High (normal) b800, no lesion visible
ADC, no lesion visible
1.7–2.1 × 10-3 mm2/s
Very high b800, hypo- or hyperintense
ADC, hyperintense
> 2.1 × 10-3 mm2/s
b800 denotes b = 800 s/mm2 images
a The qualitative appearance is always relative to the background signal. Due to the very large variations in breast
composition between women, the lesion appearance on b800 images may vary despite similar ADC values. Also,
baseline or T2-related signal variations may cause variations of the lesion appearance on b800 images as given in
the table, e.g., in case of T2 shine-through or signal blackout
b ADC values must be obtained under the following conditions: calculated from images acquiredwith the lowest b
value as specified in Table 1 and 800 s/mm2 with fat suppression, before contrast injection, diffusion time > 25
ms, and good SNR in the lesion at b = 800 s/mm2
c The given values correspond to a generic population of patients. Adjustment may be needed to account for
specific patient populations
Fig. 4 ADC thresholds and value ranges for malignant, benign, and
normal tissue. In this graph, the lower horizontal arrows show the range
of reported mean ADC values for normal breast tissue, benign, and
malignant lesions. The top arrow shows the range of suggested
thresholds to differentiate between benign and malignant lesions. Note
that this graph simply lists ranges as taken from the original tables and no
data pooling was performed. The color bars correspond to the diffusion
levels that were defined and agreed upon by the working group in order to
standardize the description of the diffusion values
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further refined to minimize variability from protocol
variation.
Which steps are necessary for further
implementation of quantitative breast DWI?
The recommendations outlined in this statement aim at
improving inter-institutional protocol consistency, increas-
ing homogeneity of reported data, and achieving a stan-
dardized assessment of the ADC values. The working
group assigns high priority to establishing ADC as a QIB
for broad diagnostic (lesion classification/aggressiveness)
and prognostic (prediction of treatment response) use.
Roadmaps for this process have been laid out by other
consortia (e.g., Quantitative Imaging Biomarkers Alliance
(QIBA, http://qibawiki.rsna.org/), Quantitative Imaging
Network (QIN), and the International Society for
Magnetic Resonance in Medicine Ad Hoc Committee on
Standards for Quantitative MR). It is expected that the
standardized acquisitions and evaluation suggested in this
document will positively contribute to this process.
Continuing efforts by (subgroups of) the working group
to address the many other parameters that may influence
acquisition and reporting of DWI will be guided by
“metrology principles” of precision, repeatability, and
reproducibility, tailored to breast imaging in particular.
As an example, physical phantoms are one key aspect of
quality control [69]. The ideal phantom mimics the target
tissue, morphologically and, in terms of MRI parameters, pro-
vides reproducible results and is either easily moved or
reproduced at multiple sites. An existing system for oncologic
imaging is based on the ice-water phantom [55, 70, 71], which
provides established ADC values and built-in temperature
Fig. 5 Clinical examples
illustrating the diffusion levels
presented in Fig. 4 and Table 2
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control. Other phantoms specifically designed for breast MRI
contain synthetic material (e.g., alkanes) mimicking the MR
properties (T1, T2, ADC) of fibroglandular, adipose, and tu-
mor tissue and built-in housings compatible with breast RF
coils [72]. It has also been shown that high ADC phantoms
such as solutions have utility in quantifying the difference
between desired (nominal) and achieved (effective) b values
[57]. In addition to ADC standardization, these systems have
the added benefit of allowing quality control of the effectively
applied b values and of fat suppression, key elements of breast
DWI. While these systems involve a higher level of invest-
ment, they may be appropriate for the future stages of inter-
site standardization envisioned by our working group.
Another element of quality control is test-retest repeat-
ability. Within breast cancer patients, obtaining this infor-
mation requires considerable commitment given the prac-
ticalities of multiple examinations, especially since normal
values may be dependent on the menstrual cycle [31, 73,
74], and likely requires evaluation in research protocols.
However, when available, it allows quantitative distinc-
tion of biologic changes from measurement imprecision,
which is vital for the use of imaging biomarkers in clinical
trials. Thus, research efforts are encouraged that collect
repeatability data in patients wherever possible to build
the evidence base.
What is the clinical potential of advanced DWI
techniques?
While the basic monoexponential diffusion model and
resulting ADC values providing a simple and technically re-
producible parameter are currently preferable in clinical prac-
tice, the working group explicitly acknowledges continuous
developments in the field of DWI that hold promise and
should be pursued in parallel with ADC standardization. For
example, the heterogeneity of ADC values within lesions may
be measured using histogram analysis and more advanced
artificial intelligence techniques [75–77]. Furthermore, DWI
techniques “beyond the ADC” [26], such as diffusion tensor
imaging (DTI), which allows the analysis of diffusion anisot-
ropy [78–83]; intravoxel incoherent motion (IVIM) imaging,
which distinguishes between intravascular perfusion and ex-
travascular microstructural diffusion components [84–89];
and non-Gaussian diffusion, which provides enhanced sensi-
tivity to tissue complexity, for instance from the kurtosis mod-
el [11, 84–88, 90–93], may enhance the value of DWI. Hybrid
combinations of these models have also been tested [11, 12].
However, such advanced methods will add constraints to the
DWI acquisition protocol (multiple diffusion-encoding direc-
tions, multiple b values in the low and high range, etc.)
resulting in longer acquisition times and the need for more
sophisticated image processing tools. Currently, there is no
reliable evidence regarding the clinical value superiority of
advanced DWI techniques over standard ADC assessment
[94]. Still, DWI users are explicitly encouraged to investigate
more specific (or “tailored”) strategies aimed at screening
(with/without the concurrent use of contrast-enhanced se-
quences), lesion characterization and staging, treatment mon-
itoring, and prognosis.
Conclusion
This statement details the first consensus on breast DWI cre-
ated by the EUSOBI International Breast DWI working
group. The working group considers breast DWI to be an
essential part of a multiparametric breast MRI protocol.
Basic requirements for routine clinical application of breast
DWI are proposed, including recommendations on b values,
fat saturation, spatial resolution, TR/TE, and considerations
for ROI placement. The working group will focus our future
efforts on expanding the technical recommendations of DWI
protocols and the development of methods for quality control.
Finally, the working group explicitly encourages research into
more sophisticated advanced acquisition, modeling, and anal-
ysis approaches to further exploit the diagnostic and prognos-
tic potential of diffusion-based breast imaging.
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